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Abstract: Aims: To examine the association of polymorphisms belonging to SLC22A1, SP1, PRPF31,
NBEA, SCNN1B, CPA6 and CAPN10 genes with glycaemic response to metformin and sulphonylureas
(SU) combination therapy among South African adults with diabetes mellitus type 2 (T2DM). Methods:
A total of 128 individuals of Swati (n = 22) and Zulu (n = 106) origin attending chronic care for T2DM
were recruited. Nine SNPs previously associated with metformin and SUs were selected and genotyped
using MassArray. Uncontrolled T2DM was defined as HbA1c > 7%. The association between genotypes,
alleles and glycaemic response to treatment was determined using multivariate logistic regression model
analysis. Results: About 85.93% (n = 110) of the study participants were female and 77.34% (n = 99) had
uncontrolled T2DM (HbA1c > 7%). In the multivariate (adjusted) logistic regression model analysis,
the CC genotype of rs2162145 (CPA6), GG and GA genotypes of rs889299 (SCNN1B) were significantly
associated with uncontrolled T2DM. On the other hand, the C allele of rs254271 (PRPF31) and the
GA genotype of rs3792269 (CAPN10) were associated with controlled T2DM. A significant interaction
between rs2162145 and rs889299 in response to metformin and SU combination therapy was observed.
Conclusions: In this study, we reported the association of rs2162145 (CC) and rs889299 (GG and GA)
with uncontrolled T2DM. We also reported the association of rs254271 (C) and rs3792269 (GA) with
controlled T2DM in response to metformin and SU combination therapy. Furthermore, an interaction
between rs2162145 and rs889299 was established, where the genotype combination GA (rs889299) and
TT (rs2162145) was associated with uncontrolled T2DM.
Keywords: type 2 diabetes; single nucleotide polymorphisms; metformin; sulphonylureas; combina-
tion therapy
1. Introduction
Diabetes mellitus (DM) is a chronic non-communicable disease that affects about
463 million people worldwide [1]. By the year 2030, the burden of DM is expected to
increase by 10.2%, reaching an estimated 578 million cases globally [1]. According to
the International Diabetes Federation (IDF), over 4.5 million South African adults were
estimated to be living with DM in the year 2019. Furthermore, over two million of these
individuals were undiagnosed and were at a higher risk for life-threatening complica-
tions associated with DM [1]. Using data from the South African National Health and
Nutrition Survey (2011–2012), Stokes et al. showed that 18.1% of South Africans were
treated but exhibited poor glycaemic control (HbA1C > 7%) [2]. Uncontrolled DM and its
complications have a huge and rapidly growing impact on the South African health care
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system [1–3]. Thus, improving glycaemic control in individuals diagnosed with DM and
initiated on treatment will require concerted efforts from many fronts including individual
behavioural changes, public health efforts and tailored medical care that is guided by
pharmacogenomics strategies.
Diabetes mellitus, particularly type 2 diabetes (T2DM), is a complex metabolic disease
that is characterised by hyperglycaemia as a consequence of defects in insulin secretion,
insulin action or a combination of both [4]. To date, there are more than ten classes of
drugs that are used to manage T2DM [5,6]. However, metformin is the only approved
anti-diabetic drug under the class of biguanides that is indicated for the treatment of
T2DM [7]. Metformin exerts its anti-diabetic properties by decreasing hepatic glucose
production, decreasing intestinal absorption of glucose and increasing insulin sensitivity.
Thus, improving glucose uptake and utilisation in peripheral tissues [8,9]. On these
grounds, metformin is the preferred initial oral anti-diabetic agent [10]. However, when
monotherapy fails to achieve glycaemic goals, combination therapy using a second agent
with a different mechanism of action is often initiated [6,11,12]. Sulphonylureas (SUs) are
characterised as insulin secretagogues, as they stimulate insulin secretion in the pancreatic
beta-cells. This class of drugs may also improve peripheral and hepatic insulin sensitivity
by reducing glucose toxicity [12–14]. The most commonly prescribed SUs are glibenclamide,
gliclazide and glimepiride [12,15,16]. These three drugs are classified as second-generation
SUs and they are the preferred add-on agents to metformin therapy [6]. Despite these
efforts, treatment with any class of anti-diabetic drug features variability that is brought by
single nucleotide polymorphisms (SNPs) in genes that are directly or indirectly implicated
in the pharmacokinetics and pharmacodynamics of anti-diabetic agents [9].
Specificity protein 1 (SP1) is a zinc finger transcription factor that binds to GC-rich
motifs of many promoters including those found in the solute carrier gene superfamily that
is responsible for metformin transport [17]. Calpain 10 (CAPN10) is calcium-dependent
cysteine proteases that is implicated in glucose metabolism and pancreatic beta-cell func-
tion [18]. Owing to their respective roles in metformin transport and glucose metabolism,
SNPs in genes coding both proteins were associated with insulin resistance, T2DM and
response to anti-diabetic drugs [19,20]. For instance, the G allele of rs3792269 (CAPN10)
was associated with an absolute reduction of HbA1c following a six-month treatment with
metformin among Caucasian patients with T2DM [21]. On the other hand, rs2683511 (SP1)
was associated with decreased metformin secretory clearance among a mixed American
cohort, however, this effect was demonstrated among healthy individuals [22].
Carboxypeptidase A6 (CPA6) is an enzyme that is encoded by the CPA6 gene. The
enzyme is responsible for catalysing the release of C-terminal amino acids and have functions
ranging from digestion to selective biosynthesis of neuroendocrine peptides [23]. On the other
hand, pre-mRNA processing factor 31 (PRPF31) encodes a ubiquitously expressed mRNA
splicing factor [24]. Furthermore, Rotroff et al. (2018) demonstrated that rs254271 (PRPF31)
was associated with decreased metformin response among patients of European and African
origin. Whilst rs2162145 of CPA6 was associated with better response to metformin in the same
study cohort, it was further demonstrated that rs57081354, an intronic polymorphism found
in the Neurobeachin (NBEA) gene, was associated with a decreased metformin response [25].
While the role of these genes in the pharmacokinetics and pharmacodynamics of metformin is
unknown, recently published data suggest that polymorphisms situated in these genes may
predict metformin response in individuals with T2DM [25].
In addition, solute carrier family 22 member 1 (SLC22A1) is a poly-specific organic
cation transporter encoded by the SLC22A1 gene that plays an important role in the influx
of metformin in hepatocytes and its elimination through the renal system [26]. A number of
SLC22A1 SNPs have been associated with variable metformin response in individuals with
T2DM [27]. For instance, it has been shown that European carriers of the del/del genotype
of rs36056065 (SLC22A1) may have a decreased but not absent risk of gastrointestinal
side effects associated with metformin [28]. On the other hand, carriers of the del/del
genotype of rs72552763 (SLC22A1) exhibited decreased hepatic distribution and exposure
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to metformin in healthy individuals residing in Denmark [26]. Moreover, Lebanese carriers
of the AC and AA genotype of rs622342 (SLC22A1) showed a greater HbA1c reduction
following metformin/SU combination therapy [29].
It was further demonstrated that rs889299 was associated with T2DM and that Euro-
pean carriers of the AA genotype may have an increased risk of oedema when treated with
glibenclamide [30]. The rs889299 polymorphism occurs in Sodium Channel Epithelial 1
Subunit Beta (SCNN1B), a gene that encodes for the beta-subunit of epithelial sodium chan-
nel (ENaC) [30]. Literature suggest that ENaC activity may be regulated by ATP-binding
cassette protein such as the K channel-associated sulfonylurea receptor [31]. Glibenclamide
is a known inhibitor of the K channel-associated sulfonylurea receptor. Furthermore, the
drug increased transepithelial Na transport in vitro [31]. On these grounds, it is possible
that rs889299 may influence glycaemic response in individuals with T2DM undergoing
SU monotherapy or metformin/SU combination therapy. Additionally, it is possible that
epistatic interactions between this variant and co-existing polymorphism may influence gly-
caemic response to metformin/SU combination therapy. This effect is yet to be established
in patients with T2DM of African descent.
It is becoming increasingly evident that a more personalised approach may be ben-
eficial in the management of T2DM. Given the dearth of pharmacogenomics researches
among individuals of African ancestry, data generated from other population groups are
unlikely to reflect the overall effect of SNPs in anti-diabetic response among Africans.
As such, there is an urgent need to investigate this identified gap with specific focus on
polymorphisms that define response to metformin/SU combination therapy in African
population. This study examines the association of nine polymorphisms belonging to
SLC22A1, SP1, PRPF31, NBEA, SCNN1B, CPA6 and CAPN10 genes with glycaemic re-
sponse to metformin/SU combination therapy among South African adults with T2DM. In
addition, the study further assesses the epistatic interactions between these SNPs and their
response to metformin/SU combination therapy.
2. Materials and Methods
2.1. Study Design and Patient Selection
Ethical clearance for this study was obtained from the Senate Research Committee of
the University of the Western Cape (Ethics clearance number BM/16/5/19). Permission to
implement the study was granted by the clinical governance of Piet Retief Hospital and the
department of Health of the Mpumalanga Provinces. All participants received information
on the purpose and procedure of the study in the home language (Swati and Zulu) prior to
signing an informed consent by each participant.
A total of 128 individuals of Swati (n = 22) and Zulu (n = 106) origin attending chronic
care for T2DM were recruited consecutively between January 2019 and June 2019, from the
outpatient department of Piet Retief Hospital, Thandukukhanya Community Health Center
and Mkhondo Town Clinic (Mkhondo, Mpumalanga). The study included participants who
were 18 years or older and were on continuous Metformin/SU dual therapy for T2DM for at
least a year prior to the study. Patients who were pregnant, diagnosed with Type 1 diabetes
mellitus, malignancies, chronic kidney and liver disease, as well as those who were undergoing
monotherapy of either insulin, metformin or any other drug for T2DM were excluded.
2.2. Data Collection
Anthropometric measurements were conducted by a trained research nurse. The
weight of each participant was measured to the nearest 0.1 kg using a digital scale (Tanita-
HD 309, Creative Health Products, MI, USA) and height to the nearest of 0.1 cm us-
ing a mounted stadiometer, with participants wearing minimal clothing. Body mass
index (BMI) for each patient was estimated as weight (kg) divided by height (m2). We
further categorised BMI as: underweight = BMI < 18.5kg/m2; normal weight = BMI:
18.5–24.9 kg/m2; overweight = BMI: 25.0–29.9 kg/m2; obese = BMI ≥ 30 kg/m2. Blood
assays for glycated haemoglobin (HbA1c) were conducted by the National Health Labora-
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tory Services (NHLS) in accordance with standardized protocols. Uncontrolled T2DM was
defined as HbA1c > 7% in accordance with the guidelines of the Society for Endocrinology,
Metabolism and Diabetes of South Africa.
Duration of T2DM and anti-diabetic drugs prescribed for each participant were re-
trieved from their clinical records. Prescribed SUs were glibenclamide, glimepiride and
gliclazide in combination with metformin. Age, ethnicity and physical activity were self-
reported and documented in a proforma designed for this study. Physical activity was
classified into active if participants engaged in rigorous physical activity that increased
heart rate, and inactive if participants did not take part in any form of physical activity.
Ethnicity was defined as belonging to a social group with a common language, cultural
tradition or ancestry; Swati or Zulu. DNA samples were collected from each participant in
the form of buccal swabs and stored at −20 ◦C until they were extracted.
2.3. DNA Isolation
Genomic DNA was isolated from buccal swabs using a standard salt lysis method [32].
Extracted DNA samples were stored at −20 ◦C. DNA was quantified using a NanoDrop™
2000/2000c UV/VIS Spectrophotometer (ThermoScientific™). SNPs were genotyped using
the MassARRAY®System IPLEX extension reaction (Agena Bioscience™). Genotypes of
the selected SNP variants were determined for all the study participants.
2.4. Selection of SNPs and Genotyping
Nine SNPs previously associated with Metformin or Sulfonylurea treatment out-
come were selected using Pharmacogenomics Knowledge Base, Ensembl as well as an
extensive survey of recent literature. Two multiplex MassARRAY systems (Agena Bio-
science TM) were designed and optimized by Inqaba Biotechnical Industries (Pretoria,
South Africa) in January 2017. Each multiplex was used to genotype selected SNPs, us-
ing an assay that is based on a locus-specific PCR reaction. This reaction is followed by
a single base extension using the mass-modified dideoxynucleotide terminators of an
oligonucleotide primer, which anneals upstream of the site of mutation. Matrix-assisted
laser desorption/ionization—time-of-flight (MALDI-TOF) mass spectrometry was used to
identify the SNP of interest.
2.5. Statistical Analysis
Statistical analyses were performed using IBM Statistical Package for Social Science
(SPSS) Version 25 for Windows (IBM Corps, Armonk, New York, NY, USA). The general
characteristics of the participants were expressed as frequency (percentages). The associa-
tions between alleles, genotypes and glycaemic response to metformin/SU combination
therapy were assessed by multivariate logistic regression model analysis (unadjusted and
adjusted odds ratios) and their 95% confidence intervals. The final model of the adjusted
logistic regression analysis included rs2162145, rs2282143, rs254271, rs2683511, rs3792269,
rs57081354, rs72552763, rs36056065 and rs622342. Results for the unadjusted logistic re-
gression model analysis were expressed as crude odds ratios (CORs) and adjusted odds
ratios (AORs) for the adjusted logistic regression model analysis. A p-value less than 0.05
was considered statistically significant. Bonferroni corrected p-values were set at <0.0125.
The minor allele frequency (MAF) and Hardy–Weinberg equilibrium (HWE) tests were
calculated using Genetic Analysis in Excel (GenAIEx) Version 6.5. SNP-SNP interactions
between rs5708135, rs2162145, rs36056065, rs622342 and rs889299 were determined using
Multi-factor dimensionality reduction (MDR) version 3.0.2. Sp1 rs2683511 (TT), rs3792269
(GG) and rs72552763 (del/del) were not detected; therefore, they were excluded from the
analysis. The best model of interaction was selected on the basis of a high cross-validation
consistency (CVC) score and p-values. p-values were calculated using x2 test, values <0.05
were deemed significant.
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3. Results
3.1. General Characteristics of the Study Cohort
A total of 128 individuals with T2DM undergoing metformin/SU combination therapy
were recruited. About 14.06% (n = 18) were male and 85.93% (n = 110) were female, of
whom 35.93% (n = 46) were aged between 55 to 65 years. Furthermore, the cohort was
comprised of 82.81% (n = 106) and 17.19% (n = 22) individuals of Zulu and Swati origin,
respectively. Majority of the study participants (68.75%) were obese (BMI ≥ 30 kg/m2),
60.93% (n = 78) were inactive, 77.34% (n = 99) had uncontrolled T2DM (HbA1c > 7%) and
73.44% (n = 94) have been living with T2D for <5 years (Table 1).
Table 1. General characteristics of the study cohort (BMI=body mass index; T2DM=type 2 diabetes mellitus).
Variable Total (n; %) Male (n; %) Female (n, %)
128 (100%) 18 (14.06) 110 (85.93)
Ethnicity
Swati 22 (17.19) 04 (22.22) 18 (16.36)
Zulu 106 (82.81) 14 (77.78) 92 (83.64)
Age
18–25 years 02 (1.56) 01 (5.55) 01 (0.91)
26–35 years 02 (1.56) 0 (0.00) 02 (1.81)
36–45 years 15 (11.72) 02 (1.56) 13 (11.81)
46–55 years 31 (24.22) 05 (27.77) 26 (23.63)
56–65 years 46 (35.93) 05 (27.77) 41 (37.27)
≥65 year 32 (25.00) 05 (27.77) 27 (24.54)
BMI
<18.5 kg/m2 01 (0.78) 0 (0.00) 01 (0.91)
18.5–24.9 kg/m2 13 (10.16) 04 (22.22) 09 (8.18)
25.0–29.9 kg/m2 26 (20.31) 06 (4.69) 20 (18.18)
≥30 kg/m2 88 (68.75) 08 (4.44) 80 (72.72)
T2DM treatment outcome
HbA1C ≤ 7% 29 (22.66) 06 (33.33) 45 (40.90)
HbA1C > 7% 99 (77.34) 12 (66.67) 65 (59.09)
Duration of Diagnosis
<5 years 94 (73.44) 13 (72.22) 81 (73.64)
≥5 years 34 (26.56) 05 (27.78) 29 (26.36)
Physical Activity
Active 50 (39.06) 08 (44.44) 42 (38.18)
Inactive 78 (60.93) 10 (55.56) 68 (61.82)
3.2. Expression and Association of SNPs with Metformin/SU Combination Therapy Response
Seven (rs2162145, rs2282143, rs254271, rs2683511, rs3792269, rs57081354, rs72552763)
out of nine SNPs were within the Hardy–Weinberg equilibrium (HWE) with p-values
ranging from 0.134–0.771 (Table 2).
In the multivariate logistic regression (unadjusted) model analysis, the CC of rs622342
(COR = 4.65; 95% CI 1.08–19.86; p = 0.038), rs889299 (COR = 3.55; 95% CI 1.11–11.33;
p = 0.032) and C allele of rs57081354 (COR = 2.15; 95% CI 1.14–4.04; p = 0.017) were sig-
nificantly associated with uncontrolled DM, whilst the G allele of rs3792269 (COR = 0.33;
95% CI 0.12–0.88; p = 0.027) was associated with controlled DM (Table 3). No associa-
tion was observed between uncontrolled DM and the genotypes or alleles of rs2162145,
rs2683511, rs36056065, rs72552763 and rs254271 (p > 0.05).
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Table 2. SNP information and Hardy–Weinberg p-values for each SNP in the study cohort.





rs2162145 CPA6 8:67747912 Intergenic T > C Metformin 0.771
rs2683511 Sp1 12:53410706 Intron C > T Metformin 0.670
rs3792269 CAPN10 2:240592062 Synonymous A > G Metformin 0.313
rs254271 PRPF31 19:54127382 Intron G > C Metformin 0.134
rs57081354 NBEA 13:35202457 Intron C > T Metformin 0.955
rs36056065 SLC22A1 Intron GTAAGTTG > del Metformin 0.002
rs622342 SLC22A1 6:160151834 Intron A > C Metformin 0.021
rs72552763 SLC22A1 6:160139849 Inframe Deletion GAT > del Metformin 0.522
rs889299 SCNN1B 16:23370593 Intron A > G Glibenclamide 0.504
Abbreviations: HWE = Hardy–Weinberg equilibrium; SNP = single nucleotide polymorphism
Table 3. Association of SNPs with glycaemic response to metformin/SU combination therapy.
dbSNP Unadjusted OddsRatios (95% CI) p-Value
Adjusted Odds







CT 2.21 (0.45–10.71) 0.323 6.67 (0.99–46.22) 0.051
CC 4.95 (0.84–29.00) 0.076 14.86 (1.71–129.04) 0.014 0.0035
Alleles
T 1 1




GC 0.29 (0.35–2.44) 0.257 0.10 (0.01–1.28) 0.077
CC 0.27 (0.03–2.36) 0.738 0.13 (0.01–1.16) 0.119
Alleles
G 1 1












G/del 0.82 (0.20–3.23) 0.777 1.47 (0.28–7.51) 0.642
del/del 0.63 (0.23–1.68) 0.358 0.60 (0.18–1.98) 0.405
Alleles
G 1 1
del 0.83 (0.28–2.43) 0.733 1.15 (0.58–2.26) 0.682
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Table 3. Conts.
dbSNP Unadjusted OddsRatios (95% CI) p-Value
Adjusted Odds















TC 0.84 (0.08–8.06) 0.885 1.37 (0.11–15.08) 0.800
TT 0.85 (0.08–8.49) 0.890 1.83 (0.14–22.87) 0.637
Alleles
T 1 1




CA 1.83 (0.58–5.71) 0.297 2.48 (0.51–12.05) 0.258
CC 4.65 (1.08–19.86) 0.038 5.84 (1.00–34.07) 0.049
Alleles
A 1 1












GG 3.55 (1.11–11.33) 0.032 7.91 (1.67–37.27) 0.009 0.00225
GA 2.66 (0.87–8.10) 0.084 5.27 (1.19–23.19) 0.028 0.007
Alleles
A 1 1
G 1.47 (0.76–2.84) 0.249 1.02 (0.48–2.15) 0.946 0.105
Abbreviations: CI = Confidence interval.
After adjusting with each SNP, the multivariate logistic regression (adjusted) model analy-
sis showed that the CC genotype rs2162145 (CPA6) (AOR = 14.86; 95% CI 1.71–29.04; p = 0.014),
GG (AOR = 7.91; 95% CI 1.67–37.27; p = 0.009) and GA (AOR = 5.27; 95% CI 1.19–23.19;
p = 0.028) genotypes of rs889299 (SCNN1B) were significantly associated with uncontrolled
T2DM. On the other hand, the C allele of rs254271 (AOR = 0.20; 95% CI 0.07–0.62; p = 0.005)
and the GA genotype of rs3792269 (CAPN10) (AOR = 0.15; 95% CI 0.02–0.85; p = 0.033) were
associated with controlled T2DM (Table 3). Polymorphisms rs2683511, rs57081354, rs36056065,
rs622342 and rs72552763 were not associated with uncontrolled DM in response to Met-
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formin/SU combination therapy (p > 0.05). The Bonferroni correction p-value was set at
< 0.0125. After Bonferroni correction, the rs3792269 (GA), rs254271 (C), rs2162145 (CC) and
rs889299 (GG and GA) remained significant with p-values < 0.0125.
3.3. Epistatic Interaction Patterns between SNPs and Their Association with Response to
Metformin/SU Combination Therapy
Epistatic interactions between CPA6, PRPF31, SLC22A1, NBEA and SCNN1B were anal-
ysed using Multifactor dimensionality reduction (MDR). The combination of rs21621459
(CPA6) and rs889299 (SCNN1B) demonstrated a high CVC score (6/10), and it was signif-
icantly associated with metformin/SU combination therapy outcome (p = 0.0022). The
combination of rs2162145 (CPA6), rs622342 (SLC22A1) and rs889299 (SCNN1B) showed a
low CVC score (5/10) (Table 4).
Table 4. Interaction models among the rs2162145, rs889299 and rs622342 in T2DM patients.
Interaction Models Training Score Testing Score CVC p-Value
CPA6 rs2162145 0.6174 0.5099 7/10 0.0107
CPA6 rs2162145 and SCNN1B rs889299 0.6749 0.4385 5/10 0.0004
CPA6 rs2162145, SLC22A1 rs622342 and SCNN1B rs889299 0.7357 0.4742 6/10 0.0001
Abbreviations: CVC = Cross-validation consistency.
The genotype combinations GA (rs889299) and TT CPA6 rs2162145, GA (rs889299) and
TC (rs2162145), and TT (rs2162145) and GG (rs889299) were prominently detected among
patients with uncontrolled T2DM (HbA1c > 7%) The combination GA (rs889299) and TT
rs2162145 was associated with uncontrolled T2DM (Figure 1). Other possible interactions
between SNPs are demonstrated in Figure 2.




Figure 1. The best Multi-factor dimensionality reduction (MDR) model of interaction among 
rs2162145 and rs889299. The distributions of Controlled (left bars) and Uncontrolled (right bars) are 
illustrated for each combination of genotypes. Each cell represents genotype combinations. Dark 
grey cells represent genotype combinations implicated in uncontrolled type 2 diabetes mellitus 
(T2DM) in response to metformin/SU treatment. light grey cell represent genotype combinations 
implicated in controlled T2DM in response to metformin/SU combination therapy. White cells rep-
resent missing data. MDR= Multi-factor dimensionality reduction 
 
Figure 2. MDR combined attribute network showing all possible interactions between single nucleotide polymorphisms 
(SNPs). Each colour represents a possible interaction. Figures and line width indicate the strength of the interaction. Fig-
ures < 1 and thin lines represent weak interactions. The strongest interactions are represented by figures ≥1 and thick lines. 
The image was generate using open-source MDR software package version 3.0.2. 
Figure 1. The best Multi-factor dimensionality reduction (MDR) model of interaction among rs2162145
and rs889299. The distributions of Controlled (left bars) and Uncontrolled (right bars) are illustrated
for each combination of genotypes. Each cell represents genotype combinations. Dark grey cells
represent gen type combinat ons implicated n uncontro led type 2 diabetes mellitus (T2DM) in re-
sponse to metformin/SU treatment. light grey cell represent genotype combinations implicated in
controlled T2DM in response to metformin/SU combination therapy. White cells represent missing data.
MDR= Multi-factor dimensionality reduction.
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Figure 2. MDR combined attribute network showing all possible interactions between single nu-
cleotide polymorphisms (SNPs). Each colour represents a possible interaction. Figures and line width
indicate the strength of the interaction. Figures < 1 and thin li es r present weak intera tions. The
stronge t interactions are represe ted by figures ≥1 a d thick lines. The imag was generate using
open-source MDR software package version 3.0.2.
4. Discussion
The combination of metformin and SUs is among the most commonly prescribed
dual therapies for the treatment of T2DM. Although widely prescribed, treatment outcome
with oral anti-diabetic drugs differs strongly between individuals due to genetic factors.
Accounting for these factors would lead to more personalised treatment regimens and
help combat the increasing prevalence of uncontrolled T2DM. Therefore, the current study
investigated the association of nine polymorphisms belonging to SLC22A1, SP1, PRPF31,
NBEA, SCNN1B, CPA6 and CAPN10 genes with glycaemic response to metformin/SU
combination therapy. The study further assessed genetic interactions between these SNPs
and glycaemic response to metformin/SU combination therapy among South African
adults with T2DM.
In this study, we investigated the effect of two SLC22A1 polymorphisms (rs36056065
and rs622342) on glycaemic response to metformin/SU combination therapy in patients
with T2DM. The CC genotype of rs622342 was significantly associated with uncontrolled
T2DM. The SLC22A1 gene plays a crucial role in metformin transport. As such, polymor-
phisms in this gene have been associated with metformin response among patients with
T2DM [33]. In a South India population, Umamaheswaran et al. [33] demonstrated that
carriers of allele C of rs622342 showed decreased response to metformin therapy. It was
further demonstrated that this effect was more pronounced among carriers of two copies
of the C allele [33]. Furthermore, Naja et al. [29] showed that Lebanese carriers of the
AC or the AA genotype exhibited better glycaemic control in individuals with T2DM
undergoing metformin/SU combination therapy. Similar effects were observed among
Egyptian patients of T2DM [34]. These findings warrant the use of this polymorphism as a
predictor of metformin/SU efficacy among patients of African origin with T2DM.
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We investigated the effect of rs2162145 (CPA6), rs57081354 (NBEA) and rs254271
(PRPF31) on glycaemic response to metformin/SU combination. Our findings suggest that
Swati and Zulu carriers of the CC genotype of rs2162145 and C allele of rs57081354 were
more likely to exhibit uncontrolled T2DM in response to metformin/SU combination ther-
apy. Whereas carriers of the minor allele C of rs254271 were more likely to exhibit controlled
T2DM in response to metformin/SU combination therapy. In a mixed cohort composed of
patients of European and African descent (African American), Rotroff et al. [25] showed
that carriers of the CT and TT genotypes of rs2162145 may have a better response to met-
formin in comparison to carriers of the CC genotype. The study further demonstrated that
carriers of the C allele of rs57081354 may have a decreased response to metformin [25].
With regards to rs254271, the authors demonstrated that Caucasian carriers of the CG
and CC genotypes may have decreased response to metformin as compared to patients
with genotype GG. Of note, this SNP was monomorphic among African Americans [25].
Literature suggest that African Americans are admixed in their African components of
ancestry, with the majority contributions being from West and West-Central Africa. As
such, the genetic architecture of African Americans is distinct from that of Africans [35].
Additionally, present day South Africans exhibit extensive genomic diversity in comparison
to other populations groups [36]. On these grounds, it is possible for rs254271 to demon-
strate different expression patterns among different groups of African origin. Genetic
diversity may also be the reason for the disparities observed in the direction of association
of the minor allele among people of European ancestry and South Africa Nguni people.
Additional investigations conducted in a more diverse South African cohort are required
to confirm the clinical impact of rs254271, rs2162145 and rs57081354 and further explore
their potential as predictors of glycaemic response to anti-diabetic drugs.
In addition, the G allele and AG genotype of rs3792269 (CAPN10) were significantly asso-
ciated with controlled T2DM in response to metformin/SU combination therapy in our cohort
of South African Nguni (Swati and Zulu). The CAPN10 gene encodes calcium-dependent
intracellular protease that is important in calcium-regulated signalling pathways [21]. The
variant rs3792269 of CAPN10 was previously associated with the preventive effect of met-
formin on the development of T2DM in subjects with pre-diabetic dysglycaemia [37]. This
effect was observed among Caucasian carriers of the G allele who reside in Slovakia. However,
the preventative effect of this SNP on the development of T2DM is yet to be established among
people of African origin. In addition to preventing T2DM, it was demonstrated that European
carriers of the minor allele G had a smaller probability of achieving HbA1c < 7% and they had
a smaller reduction in HbA1c during the first six months of metformin treatment [21]. The
differences observed in both studies could be explained by several factors. For instance, our
study sampled patients who were on combination therapy, while Tkáč et al. [21] investigated
patients on metformin monotherapy. Additionally, our study population of South African
Nguni is different from the Central European Caucasian patients that were used in the refer-
ence study. While the direction of association of the genotypes and minor allele differed from
previous findings, this SNP is proving to be of relevance in anti-diabetic treatment response
among patients with T2DM.
In the present study, the GA and GG genotype of rs889299 were associated with
uncontrolled T2DM in response to metformin/SU combination therapy. The A allele of the
variant was previously associated with oedema in diabetic patients treated with Farglitazar
and glibenclamide among Caucasians who reside in the United Kingdom (UK) [30]. The
SNP rs889299 occur on the intronic region of SCNN1B, a gene that is responsible for
providing instructions for the construction of the beta-subunit of ENac [30]. The activity
of ENac is regulated by ATP-binding cassette protein such as the K channel-associated
sulfonylurea receptor [31]. The K channel-associated sulfonylurea receptor is responsible
for maintain energy balance within a living cell [14,38]. Sulphonylureas binds specific
sites of this receptor, thereby blocking the inflow of K+ and stimulating the diffusion of
Ca+ into the cytosol. This activity leads to the contraction of the filaments of actomyosin
responsible for the exocytosis of insulin granules, which is; therefore, promptly secreted in
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large amounts [14,38]. While metformin has no effect on SCNN1B, its mechanism of action
complements that of SUs by improving insulin sensitivity [11]. On these grounds, rs889299
can be used as a predictor for SU monotherapy or metformin/SU combination therapy.
There is currently no record of the effect of rs889299 on glycaemic response to metformin
and SU monotherapy or combination therapy. To the best of our knowledge, this is the first
study to explore the effect of this polymorphism on glycaemic response to metformin/SU
combination therapy in a population of African origin.
In the current study, we investigated genetic interactions between rs5708135 (NBEA),
rs2162145 (CPA6), rs36056065 (SLC22A1), rs622342 (SLC22A1) and rs889299 (SCNN1B) and
their effect on metformin/SU combination response. An interaction between rs2162145
and rs889299 was observed. Furthermore, the combination of TT (rs2162145) and GG
(rs889299) as well as GA (rs889299) and TT (rs2162145) were prominently detected among
uncontrolled patients. The GA (rs889299) and TT (rs2162145) combination was implicated
in uncontrolled T2DM. Of note, the TT genotype of rs2162145 was associated with better
response to metformin. The effect of this SNP may depend on the presence of rs889299, sug-
gesting that both SNPs may synergistically influence glycaemic response to metformin/SU
combination therapy among South African Nguni patients. The importance of gene-gene
or SNP-SNP interactions is gaining recognition in the field of pharmacogenomics [39].
Epistatic interactions between rs594709 and rs2289669 in metformin efficacy among Chi-
nese patients with T2D were reported by Xiao et al. (2016). Furthermore, Naja et al. [29]
reported interactions between rs622342 (SLC22A1) and CYP2C9*2 and CYP2C9*3 associated
with reduced levels of HbA1c in response to metformin/SU combination therapy among
Lebanese patients. Only a few studies have explored this phenomenon with regards to
anti-diabetic drugs; however, the importance of epistasis in anti-diabetic therapy is clearly
identifiable. These findings have laid a foundation for the investigation of the complex
interactions among genetic, and epigenetic factors that influence glycaemic response in
metformin/ SU combination therapy among T2DM patients.
5. Limitations
Few limitations of the study cannot be ignored. The cross-sectional design does not
allow for causal relationship to be established. Wide confidence interval and the high
CVC score for the MDR model of interaction observed in the relationship between the
SNPs and the glycaemic control is due largely to the small sample size. The absence of
rs2683511 (TT), rs3792269 (GG) and rs72552763 (del/del) is noted. These genotypes were
needed to better assess interaction effects that exist between these SNPs and glycaemic
response to metformin/SU combination therapy. This is a health facility-based study with
strict selection criteria (participants should have been initiated on combination therapy of
metformin and SUs for at least a year at the time of the study). Thus, men were under-
represented in the study due to their low utilisation of health facilities in the region. Low
utilisation of health facilities by men has been reported extensively across South Africa. The
proportion of men who utilise the healthcare system in the Eastern Cape Province ranged
from 28.30% to 32.16%, as demonstrated by Adeniyi et al. [40] and Owolabi et al. [41].
Motala et al. [42], Adebolu et al. [43] and Olowe et al. [44] reported utilisation rates
ranging between 20.48% and 30.00% in the KwaZulu Natal province. In the Western Cape,
Erasmus et al. [45] and Peer et al. [46] reported rates ranging from 19.36 to 35.66%. Future
studies should specifically target men and other ethnic populations at the community
level in order to gain better understanding of the associations between SNPs on glycaemic
response to metformin/SU combination therapy. Notwithstanding of these limitations, this
study provides new insights into pharmacogenomics of metformin/SUs in South African
adults with T2DM. In addition, this study has opened doors for pharmacogenomic studies
in the ethnically-diverse population of South Africa.
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6. Conclusions
This study reports the association of rs2162145 (CC), rs889299 (GA and GG) and
SLC22A1 rs622342 (CC) and rs57081354 (C) with uncontrolled T2DM in response to met-
formin/SU combination therapy in South Africa. The study also reports an association of
rs254271 (C) and rs3792269 (G allele and genotype AG) with controlled T2DM. Furthermore,
the study established an interaction between rs889299 and rs2162145 that is implicated
in metformin/SU treatment outcome in an indigenous South African population. Fur-
ther, pharmacogenomics and functional investigations should be conducted in a bigger
South African cohort to confirm the effects of these genetic variants on metformin/SU
combination therapy and provide more powerful evidence for their use as predictors of
anti-diabetic treatment response.
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